Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-001 in healthy volunteers
NCT06294275Phase 1Completed
- Sponsor
- LongBio Pharma
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of LP-001 in myelodysplastic syndrome (MDS) (10 cohorts), sponsored by LongBio Pharma. Primary endpoint: Adverse Events at 36 days. Started Sep 2022; status: completed.
02
Drugs
LP-001
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06294275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294275.